

## PRARAM 9 HOSPITAL

## PR9 TB

THAILAND / HEALTHCARE

BUY

UNCHANGED

## ผลประกอบการ 3Q22 น่าจะฟื้นตัวกลับมาอยู่ในเกณฑ์ดี

- คาดกำไร 3Q22 จะโต 7% q-q และ 62% y-y มาอยู่ที่ 134 ลบ. นำโดยรายได้จากผู้ป่วยชาวไทยที่ไม่ได้เป็นโควิดและจากผู้ป่วยต่างชาติที่อาศัยอยู่ในประเทศไทย (Expat) ที่สูงขึ้น
- รายได้จากผู้ป่วยต่างชาติปรับตัวขึ้นสูงกว่าช่วงก่อนโควิดจากผู้ป่วยต่างชาติที่อาศัยอยู่ในประเทศไทยไปแล้ว; Upside จากผู้ป่วยต่างชาติที่บินเข้ามารับการรักษา (Fly-in) ซึ่งกำลังฟื้นตัวต่อเนื่อง
- คงแนะนำซื้อหลังปรับราคาเป้าหมายขึ้นเป็น 21 บาท (DCF)

TARGET PRICE	THB21.00
CLOSE	THB16.90
UP/DOWNSIDE	+24.3%
PRIOR TP	THB18.00
CHANGE IN TP	+16.7%
TP vs CONSENSUS	+9.6%

## KEY STOCK DATA

YE Dec (THB m)	2021	2022E	2023E	2024E
Revenue	2,987	4,005	4,117	4,325
Net profit	249	540	566	614
EPS (THB)	0.32	0.69	0.72	0.78
vs Consensus (%)	-	6.0	3.0	8.6
EBITDA	590	966	1,009	1,086
Core net profit	249	540	566	614
Core EPS (THB)	0.32	0.69	0.72	0.78
Chg. In EPS est. (%)	-	11.3	15.0	11.2
EPS growth (%)	23.3	116.7	4.8	8.5
Core P/E (x)	53.3	24.6	23.5	21.6
Dividend yield (%)	0.8	2.8	3.0	3.2
EV/EBITDA (x)	20.4	12.0	11.4	10.3
Price/book (x)	3.1	2.8	2.7	2.6
Net debt/Equity (%)	(28.9)	(35.1)	(36.6)	(40.3)
ROE (%)	5.9	12.0	11.8	12.3

## รายได้ 3Q22 จะสูงเป็นประวัติการณ์ถึง 1 พัน ลบ.

ใน 3Q22 เราคาดว่ารายได้จะโต 5% q-q โดยรายได้จากผู้ป่วยชาวไทยน่าจะโต 9% q-q จากฤดูกาลรักษาพยาบาลในประเทศไทย (ฤดูฝน) สัดส่วนรายได้โควิดน่าจะชะลอตัวลดลงจาก 13% ของระดับก่อนโควิดใน 2Q22 เป็น 8% ใน 3Q22 เราคาดว่ารายได้จากผู้ป่วยต่างประเทศจะกระโดดเพิ่ม 22% q-q จากผู้ป่วย Expat ค่าใช้จ่ายการขายและการบริหารน่าจะเพิ่ม 5% q-q เนื่องจาก PR9 ได้ปรับเพิ่มต้นทุนเพื่อรักษาบุคลากรโดยเฉพาะอย่างยิ่งคือกลุ่มพยาบาล EBITDA margin รวมน่าจะทรงตัว q-q ที่ 23% ซึ่งจะช่วยให้กำไรเติบโต 7% q-q มาอยู่ที่ 134 ลบ. ซึ่งสูงกว่าระดับก่อนโควิดถึง 51%

## การฟื้นตัวของ Fly-in จะเป็นปัจจัยหนุนตัวต่อไป


รายได้จากผู้ป่วยต่างชาติได้ปรับตัวขึ้นสูงกว่าระดับก่อนโควิดไปแล้ว 20% ใน 2Q22 และเราคาดว่าตัวเลขดังกล่าวจะสูงกว่าระดับก่อนโควิดถึง 32% ใน 3Q22 ปัจจัยหนุนสำคัญน่าจะอยู่ที่รายได้จาก Expat ที่สูงขึ้น ผู้บริหารคาดว่าสัดส่วนระหว่าง Fly-in และ Expat จะอยู่ที่ 50:50 ใน 2Q-3Q22 เทียบกับที่ 70:30 ก่อนโควิด ตัวเลขดังกล่าวชี้ให้เห็นว่ามีโอกาสที่ปริมาณผู้ป่วย Fly-in จะเพิ่มสู่ระดับก่อนโควิด ตลาดผู้ป่วย Fly-in สำคัญอยู่ที่พม่าและกัมพูชา PR9 คาดว่าจะจับกลุ่มตลาดผู้ป่วย Fly-in ชาวจีนในปีหน้าเมื่อประเทศจีนกลับมาเปิดพรมแดน เราคาดว่าสัดส่วนรายได้จากผู้ป่วยต่างชาติจะเพิ่มเป็น 20-30% ภายในปี 2024 จาก 13% ใน 2Q22

## แนวโน้มจะดีต่อเนื่องใน 4Q22

เราคาดว่ารายได้จะโตต่อเนื่องใน 4Q22 ซึ่งน่าจะเป็นไตรมาสที่มีรายได้สูงสุดในปีนี้จากศูนย์ตรวจสุขภาพซึ่งผู้ป่วยมีแนวโน้มใช้ในไตรมาสสุดท้ายของปีและศูนย์ทำเลสิกซึ่งผู้ป่วยจะใช้ในช่วงวันหยุดยาว เราคาดว่ารายได้จะโต 34% เป็น 4 พัน ลบ. ในปี 2022 สูงกว่าเป้าหมายของผู้บริหารที่ 3.9 พัน ลบ. อยู่เล็กน้อย

## ปรับเพิ่มประมาณการกำไร; มูลค่าต่ำกว่าค่าเฉลี่ยกลุ่ม

เราปรับเพิ่มประมาณการกำไรไปในปี 2022-24 ขึ้น 11-15% เพื่อสะท้อนแนวโน้มธุรกิจที่อยู่ในเกณฑ์ดีและได้ราคาเป้าหมายใหม่ที่ 21 บาท (DCF) ในพื้นที่เราทำการศึกษากว่า PR9 น่าจะเป็นหนึ่งในหุ้นการแพทย์ที่รายงานกำไร 3Q22 โต q-q พร้อม BDMS และ BH ในขณะที่ระดับมูลค่าของ PR9 ยังน่าสนใจโดยมีการซื้อขายที่เพียง 24x ของค่า 2023E P/E (เทียบกับค่าเฉลี่ยของกลุ่ม) ที่ 34x และของ BDMS และ BH ที่ 36-40x)



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	(7.7)	7.6	59.4
Relative to country (%)	(2.7)	6.8	66.4
Mkt cap (USD m)			351
3m avg. daily turnover (USD m)			1.3
Free float (%)			59
Major shareholder	Khunying Potjaman Damapong (37%)		
12m high/low (THB)	19.20/10.60		
Issued shares (m)	786.30		

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA

teerapol.udo@fssia.com

+66 2611 3535

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

บทวิเคราะห์ฉบับนี้แปลมาจากบทวิเคราะห์ของ FSSIA ฉบับวันที่ 11 ตุลาคม 2022

## Investment thesis

PR9 is a standalone hospital that is known as a “value-for-money” hospital. It recently upgraded the hospital to include tertiary care with new specialist centres. One of the top contributors is the Kidney Transplant Institute, which is the only facility to be accredited by Joint Commission International (JCI) outside the US.

The hospital is in a growth phase, with its new building having opened in July 2020. The new building enables PR9 to capture new customer groups from its new specialist centres and gives it a higher IPD capacity.

The improving EBITDA margin and ROE should lead to its stock valuation re-rating, in our view.


## Company profile

PR9 has been operating a private hospital since 1992.

[www.praram9.com](http://www.praram9.com)

## Principal activities (revenue, 2021)


- OPD patient revenue - 54.2 %
- IPD patient revenue - 45.8 %



Source: Praram 9 Hospital

## Major shareholders

- Khunying Potjaman Damapong - 37.1 %
- N.C.B.TRUST LIMITED-NORGES BANK 33 - 2.6 %
- Thai NVDR - 2.2 %
- Bualuang Basic Dividend LTF - 1.8 %
- Others - 56.3 %



Source: Praram 9 Hospital

## Catalysts

Key potential growth drivers include 1) a higher Thai patient volume from new specialist centres; and 2) rising demand from medical tourists, especially patients from Cambodia, Laos, Myanmar and Vietnam (CLMV), as well as China.

## Risks to our call

Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.

## Event calendar

Date	Event
Nov 2022	3Q22 results announcement

## Key assumptions

	2022E	2023E	2024E
	(%)	(%)	(%)
No. of licensed beds (no.)	229	249	270
OPD volume growth	23	0	3
OPD revenue / patient growth	11	1	2
IPD volume growth	23	5	3
IPD revenue / patient growth	7	0	2

Source: FSSIA estimates

## Earnings sensitivity

- For every 1% increase in patient volume, we project 2022 earnings to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in EBITDA margin, we project 2022 earnings to rise by 7%, and vice versa, all else being equal.

Source: FSSIA estimates




## Exhibit 1: 3Q22 results preview

FY ending Dec	3Q21	4Q21	1Q22	2Q22	3Q22E	----- Change -----		2022E	Change
	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(q-q %)	(y-y %)	(THB m)	(y-y %)
Sales	751	935	970	970	1,021	5	36	4,005	34
COGS (incl depreciation)	(526)	(644)	(627)	(664)	(692)	4	32	(2,708)	25
<b>Gross profit</b>	<b>225</b>	<b>291</b>	<b>343</b>	<b>306</b>	<b>329</b>	<b>7</b>	<b>46</b>	<b>1,296</b>	<b>59</b>
SG&A	(134)	(161)	(159)	(164)	(172)	5	29	(669)	20
<b>Operating profit</b>	<b>91</b>	<b>130</b>	<b>184</b>	<b>142</b>	<b>157</b>	<b>10</b>	<b>73</b>	<b>627</b>	<b>144</b>
Net other income	10	12	10	12	11	(5)	11	48	11
Interest expenses	(0)	(0)	(0)	(0)	0	(100)	(100)	(0)	n/a
<b>Pretax profit</b>	<b>101</b>	<b>142</b>	<b>194</b>	<b>154</b>	<b>168</b>	<b>9</b>	<b>67</b>	<b>675</b>	<b>125</b>
Income Tax	(18)	(26)	(37)	(29)	(34)	16	91	(135)	164
<b>Core profit</b>	<b>83</b>	<b>116</b>	<b>157</b>	<b>125</b>	<b>134</b>	<b>7</b>	<b>62</b>	<b>540</b>	<b>117</b>
Extraordinaries, GW & FX									
<b>Reported net profit</b>	<b>83</b>	<b>116</b>	<b>157</b>	<b>125</b>	<b>134</b>	<b>7</b>	<b>62</b>	<b>540</b>	<b>117</b>
Outstanding shares (m)	786	786	786	786	786	0	0	786	0
<b>Pre-ex EPS (THB)</b>	<b>0.11</b>	<b>0.15</b>	<b>0.20</b>	<b>0.16</b>	<b>0.17</b>	<b>7</b>	<b>62</b>	<b>0.69</b>	<b>117</b>
<b>EPS (THB)</b>	<b>0.11</b>	<b>0.15</b>	<b>0.20</b>	<b>0.16</b>	<b>0.17</b>	<b>7</b>	<b>62</b>	<b>0.69</b>	<b>117</b>
COGS excl. depreciation	(453)	(567)	(553)	(588)	(619)	5	37	(2,413)	28
Depreciation	(73)	(77)	(74)	(75)	(73)	(3)	(1)	(296)	1
EBITDA	174	218	268	229	241	5	38	971	63
<b>Key ratios</b>	<b>(%)</b>	<b>(%)</b>	<b>(%)</b>	<b>(%)</b>	<b>(%)</b>	<b>(ppt)</b>	<b>(ppt)</b>	<b>(%)</b>	<b>(ppt)</b>
Gross margin	30	31	35	32	32	1	2	32	5
SG&A/Revenue	18	17	16	17	17	(0)	(1)	17	(2)
EBITDA margin	23	23	27	23	23	(0)	0	24	4
Net profit margin	11	12	16	13	13	0	2	13	5
<b>Operating stats</b>	<b>(%)</b>	<b>(%)</b>	<b>(%)</b>	<b>(%)</b>					
OPD revenue growth y-y	(10)	32	50	61					
OPD volume growth y-y	(16)	10	26						
OPD revenue per head growth y-y	7	19	19						
IPD revenue growth y-y	32	21	40	44					
IPD volume growth y-y	75	19	82						
IPD revenue per head growth y-y	(25)	2	(23)						
Thai patient revenue growth y-y	8	26	42	47					
Inter patient revenue growth y-y	13	51	77	114					


Sources: PR9; FSSIA estimates

### Exhibit 2: Non-Covid Thai patient revenue




Sources: PR9; FSSIA estimates

### Exhibit 3: International patient revenue




Sources: PR9; FSSIA estimates

### Exhibit 4: Covid-related revenue




Sources: PR9; FSSIA estimates

### Exhibit 5: EBITDA margin




Sources: PR9; FSSIA estimates

### Exhibit 6: Covid-related and international patient revenue contributions



Sources: PR9; FSSIA estimates

### Exhibit 7: Core profit



Source: Bloomberg

## Exhibit 8: Forecast revisions

	Current			Previous			Change		
	2022E	2023E	2024E	2022E	2023E	2024E	2022E	2023E	2024E
	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(%)	(%)	(%)
Revenue	4,005	4,117	4,325	3,799	3,837	4,051	5.4	7.3	6.8
EBITDA margin (%)	24.1	24.5	25.1	23.6	23.9	24.9	0.5	0.6	0.3
Core profit	540	566	614	485	492	552	11.4	15.1	11.2
<b>Key assumptions</b>									
OPD- Visits per day (no.)	1,333	1,333	1,373	1,278	1,278	1,310	4.2	4.2	4.7
OPD - Revenue per visit (THB)	4,535	4,580	4,672	4,413	4,457	4,590	2.8	2.8	1.8
IPD - Admissions per day (no.)	33	35	36	32	32	33	3.4	8.5	9.1
IPD - Revenue per admission (THB)	148,358	148,358	151,326	148,358	149,842	154,337	0.0	(1.0)	(2.0)

Note: Change of items in percentage terms are represented in ppt change


Source: FSSIA estimates

## Exhibit 9: DCF valuation

Cost of equity assumptions	(%)		Cost of debt assumptions	(%)
Risk-free rate	3.0		Pre-tax cost of debt	3.5
Market risk premium	8.0		Marginal tax rate	20.0
Stock beta	0.8			
Cost of equity, Ke	9.4		Net cost of debt, Kd	2.8
Weight applied	100.0		Weight applied	0.0
WACC	9.4			
DCF valuation estimate	(THB b)	(THB/share)	Comments	
NPV	5.7	7.3	WACC 9.4%, risk-free rate 3%, risk premium 8%	
Terminal value	9.0	11.5	Terminal growth 3%	
Cash & liquid assets	1.8	2.3	At end-2023E	
Investments	0.0	0.0	At end-2023E	
Debt	(0.0)	(0.0)	At end-2023E	
Minorities	0.0	0.0	At end-2023E	
<b>Residual ordinary equity</b>	<b>16.5</b>	<b>21.0</b>		


Source: FSSIA estimates

## Exhibit 10: Historical P/E band



Sources: Bloomberg; FSSIA estimates

## Exhibit 11: Historical EV/EBITDA band



Sources: Bloomberg; FSSIA estimates

## Exhibit 12: Peer comparisons as of 10 October 2022

Company	BBG	Rec	----- Share price -----			Market Cap (USD m)	---- PE ----		---- ROE ----		---- PBV ----		- EV/ EBITDA -	
			Current (LCY)	Target (LCY)	Upside (%)		22E (x)	23E (x)	22E (%)	23E (%)	22E (x)	23E (x)	22E (x)	23E (x)
<b>Thailand</b>														
Bangkok Dusit Med Service	BDMS TB	BUY	29.00	33.00	14	12,157	40.6	35.7	13.2	14.2	5.2	4.9	21.7	19.4
Bumrungrad Hospital	BH TB	BUY	233.00	235.00	1	4,885	44.4	39.8	23.1	23.3	9.8	8.8	28.2	25.6
Bangkok Chain Hospital	BCH TB	BUY	17.30	28.50	65	1,138	9.3	21.8	33.7	13.7	2.9	3.0	5.9	11.1
Chularat Hospital	CHG TB	BUY	3.54	4.70	33	1,027	12.9	26.7	37.8	17.7	4.6	4.8	8.6	15.8
Praram 9 Hospital	PR9 TB	BUY	16.90	21.00	24	351	24.6	23.5	12.0	11.8	2.8	2.7	12.0	11.4
Thonburi Healthcare Group	THG TB	REDUCE	67.00	45.00	(33)	1,498	39.8	79.8	15.1	7.4	5.8	6.0	22.7	31.7
Vibhavadi Medical Center	VIBHA TB	BUY	2.94	3.20	9	1,053	38.1	36.8	8.1	7.3	2.7	2.7	33.3	30.1
Ramkhamhaeng Hospital	RAM TB	BUY	55.25	62.00	12	1,749	31.6	31.0	11.8	11.3	3.6	3.4	29.1	25.3
Principal Capital	PRINC TB	BUY	6.10	10.00	64	613	27.0	24.7	8.4	8.5	2.2	2.1	14.6	13.8
Rajthanee Hospital	RJH TB	n/a	33.75	n/a	n/a	266	8.7	22.6	52.1	20.3	6.8	4.3	6.8	15.2
Ekachai Medical Care	EKH TB	n/a	8.05	n/a	n/a	140	26.0	26.1	15.2	14.1	5.7	3.4	15.6	14.8
<b>Thailand average</b>						<b>24,875</b>	<b>27.6</b>	<b>33.5</b>	<b>20.9</b>	<b>13.6</b>	<b>4.7</b>	<b>4.2</b>	<b>18.0</b>	<b>19.5</b>
<b>Regional</b>														
Ramsay Health Care	RHC AU	n/a	56.62	n/a	n/a	8,231	41.3	30.1	8.3	11.4	3.2	3.2	12.6	11.2
Ihh Healthcare Bhd	IHH SP	n/a	1.71	n/a	n/a	10,591	31.4	26.9	6.8	7.0	1.9	1.9	13.9	13.1
Ryman Healthcare	RYM NZ	n/a	8.45	n/a	n/a	2,356	18.5	15.4	7.4	7.6	1.3	1.3	18.5	14.3
Apollo Hospitals Enterprise	APHS IN	n/a	4,341	n/a	n/a	7,572	67.6	60.7	18.6	16.7	11.0	11.0	28.6	28.2
Kpj Healthcare Berhad	KPJ MK	n/a	0.80	n/a	n/a	738	29.3	21.9	5.3	7.2	1.6	1.6	11.8	10.5
Raffles Medical Group	RFMD SP	n/a	1.26	n/a	n/a	1,624	24.2	25.2	9.8	9.0	2.4	2.4	12.8	13.3
Mitra Keluarga Karyasehat	MIKA IJ	n/a	2,790	n/a	n/a	2,595	36.3	32.7	19.6	20.0	6.9	6.9	23.7	21.1
Aier Eye Hospital Group	300015 CH	n/a	27.60	n/a	n/a	27,048	60.9	46.6	21.7	23.5	13.0	13.0	37.3	29.2
<b>Regional average</b>						<b>60,756</b>	<b>38.7</b>	<b>32.4</b>	<b>12.2</b>	<b>12.8</b>	<b>5.2</b>	<b>5.2</b>	<b>19.9</b>	<b>17.6</b>
<b>Overall average</b>						<b>85,632</b>	<b>32.2</b>	<b>33.1</b>	<b>17.3</b>	<b>13.3</b>	<b>4.9</b>	<b>4.6</b>	<b>18.8</b>	<b>18.7</b>

Sources: Bloomberg; FSSIA estimates

## Financial Statements

### Praram 9 Hospital

Profit and Loss (THB m) Year Ending Dec	2020	2021	2022E	2023E	2024E
Revenue	2,601	2,987	4,005	4,117	4,325
Cost of goods sold	(1,677)	(1,879)	(2,413)	(2,458)	(2,569)
<b>Gross profit</b>	<b>925</b>	<b>1,108</b>	<b>1,592</b>	<b>1,659</b>	<b>1,756</b>
Other operating income	38	39	43	46	48
Operating costs	(518)	(557)	(669)	(696)	(718)
<b>Operating EBITDA</b>	<b>444</b>	<b>590</b>	<b>966</b>	<b>1,009</b>	<b>1,086</b>
Depreciation	(213)	(294)	(296)	(308)	(326)
Goodwill amortisation	-	-	-	-	-
<b>Operating EBIT</b>	<b>231</b>	<b>297</b>	<b>670</b>	<b>701</b>	<b>760</b>
Net financing costs	0	4	5	7	7
Associates	0	0	0	0	0
Recurring non-operating income	0	0	0	0	0
Non-recurring items	0	0	0	0	0
<b>Profit before tax</b>	<b>230</b>	<b>300</b>	<b>675</b>	<b>707</b>	<b>767</b>
Tax	(28)	(51)	(135)	(141)	(153)
<b>Profit after tax</b>	<b>202</b>	<b>249</b>	<b>540</b>	<b>566</b>	<b>614</b>
Minority interests	0	0	0	0	0
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
<b>Reported net profit</b>	<b>202</b>	<b>249</b>	<b>540</b>	<b>566</b>	<b>614</b>
<b>Non-recurring items &amp; goodwill (net)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Recurring net profit</b>	<b>202</b>	<b>249</b>	<b>540</b>	<b>566</b>	<b>614</b>
<b>Per share (THB)</b>					
Recurring EPS *	0.26	0.32	0.69	0.72	0.78
Reported EPS	0.26	0.32	0.69	0.72	0.78
DPS	0.11	0.14	0.48	0.50	0.55
Diluted shares (used to calculate per share data)	786	786	786	786	786
<b>Growth</b>					
Revenue (%)	(8.7)	14.8	34.1	2.8	5.1
Operating EBITDA (%)	(17.8)	33.0	63.6	4.5	7.6
Operating EBIT (%)	(38.5)	28.5	126.0	4.6	8.5
Recurring EPS (%)	(35.3)	23.3	116.7	4.8	8.5
Reported EPS (%)	(29.0)	23.3	116.7	4.8	8.5
<b>Operating performance</b>					
Gross margin inc. depreciation (%)	27.4	27.3	32.4	32.8	33.1
Gross margin of key business (%)	27.4	27.3	32.4	32.8	33.1
Operating EBITDA margin (%)	17.1	19.8	24.1	24.5	25.1
Operating EBIT margin (%)	8.9	9.9	16.7	17.0	17.6
Net margin (%)	7.8	8.3	13.5	13.7	14.2
Effective tax rate (%)	12.3	17.0	20.0	20.0	20.0
Dividend payout on recurring profit (%)	42.8	44.2	70.0	70.0	70.0
Interest cover (X)	491.0	(79.4)	(138.1)	(106.2)	(105.6)
Inventory days	10.7	10.2	9.7	10.8	10.7
Debtor days	22.1	22.7	21.2	24.2	24.8
Creditor days	98.8	101.4	103.2	114.9	113.5
Operating ROIC (%)	6.9	7.7	16.9	17.5	19.0
ROIC (%)	6.7	7.5	16.6	17.1	18.6
ROE (%)	5.0	5.9	12.0	11.8	12.3
ROA (%)	4.3	5.0	9.8	9.6	10.0
* Pre-exceptional, pre-goodwill and fully diluted					
<b>Revenue by Division (THB m)</b>					
OPD patient revenue	1,461	1,620	2,206	2,228	2,341
IPD patient revenue	1,140	1,367	1,799	1,889	1,984

Sources: Praram 9 Hospital; FSSIA estimates



## Financial Statements

### Praram 9 Hospital

Cash Flow (THB m) Year Ending Dec	2020	2021	2022E	2023E	2024E
Recurring net profit	202	249	540	566	614
Depreciation	213	294	296	308	326
Associates & minorities	-	-	-	-	-
Other non-cash items	98	3	0	0	0
Change in working capital	(34)	27	106	(29)	30
<b>Cash flow from operations</b>	<b>480</b>	<b>574</b>	<b>941</b>	<b>845</b>	<b>970</b>
Capex - maintenance	(806)	(235)	(418)	(325)	(307)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	0	0	0	0	0
Other investments (net)	-	-	-	-	-
<b>Cash flow from investing</b>	<b>(806)</b>	<b>(235)</b>	<b>(418)</b>	<b>(325)</b>	<b>(307)</b>
Dividends paid	(110)	(86)	(110)	(378)	(396)
Equity finance	0	0	0	0	0
Debt finance	8	(2)	0	0	0
Other financing cash flows	(8)	0	0	0	0
<b>Cash flow from financing</b>	<b>(110)</b>	<b>(88)</b>	<b>(110)</b>	<b>(378)</b>	<b>(396)</b>
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
<b>Net other adjustments</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Movement in cash</b>	<b>(437)</b>	<b>250</b>	<b>413</b>	<b>142</b>	<b>267</b>
Free cash flow to firm (FCFF)	(326.28)	338.71	523.49	520.20	663.85
Free cash flow to equity (FCFE)	(326.86)	336.58	523.07	519.78	663.42

#### Per share (THB)

FCFF per share	(0.41)	0.43	0.67	0.66	0.84
FCFE per share	(0.42)	0.43	0.67	0.66	0.84
Recurring cash flow per share	0.65	0.69	1.06	1.11	1.20

Balance Sheet (THB m) Year Ending Dec	2020	2021	2022E	2023E	2024E
Tangible fixed assets (gross)	5,345	5,565	5,984	6,309	6,615
Less: Accumulated depreciation	(1,812)	(2,090)	(2,386)	(2,694)	(3,020)
<b>Tangible fixed assets (net)</b>	<b>3,533</b>	<b>3,475</b>	<b>3,597</b>	<b>3,614</b>	<b>3,595</b>
<b>Intangible fixed assets (net)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	4	4	4	4	4
Cash & equivalents	994	1,244	1,657	1,799	2,066
A/C receivable	159	212	252	294	294
Inventories	49	56	72	73	77
Other current assets	6	90	121	124	130
<b>Current assets</b>	<b>1,208</b>	<b>1,603</b>	<b>2,103</b>	<b>2,290</b>	<b>2,567</b>
Other assets	52	55	55	55	55
<b>Total assets</b>	<b>4,797</b>	<b>5,137</b>	<b>5,759</b>	<b>5,964</b>	<b>6,222</b>
Common equity	4,115	4,278	4,708	4,896	5,114
Minorities etc.	0	0	0	0	0
<b>Total shareholders' equity</b>	<b>4,115</b>	<b>4,278</b>	<b>4,708</b>	<b>4,896</b>	<b>5,114</b>
Long term debt	8	6	6	6	6
Other long-term liabilities	182	190	190	190	190
<b>Long-term liabilities</b>	<b>190</b>	<b>196</b>	<b>196</b>	<b>196</b>	<b>196</b>
A/C payable	446	597	767	781	816
Short term debt	0	0	0	0	0
Other current liabilities	45	66	88	91	96
<b>Current liabilities</b>	<b>492</b>	<b>663</b>	<b>855</b>	<b>872</b>	<b>912</b>
<b>Total liabilities and shareholders' equity</b>	<b>4,797</b>	<b>5,137</b>	<b>5,759</b>	<b>5,964</b>	<b>6,222</b>
Net working capital	(277)	(305)	(410)	(381)	(411)
Invested capital	3,311	3,230	3,246	3,293	3,243

\* Includes convertibles and preferred stock which is being treated as debt

#### Per share (THB)

Book value per share	5.23	5.44	5.99	6.23	6.50
Tangible book value per share	5.23	5.44	5.99	6.23	6.50

#### Financial strength

Net debt/equity (%)	(24.0)	(28.9)	(35.1)	(36.6)	(40.3)
Net debt/total assets (%)	(20.6)	(24.1)	(28.7)	(30.1)	(33.1)
Current ratio (x)	2.5	2.4	2.5	2.6	2.8
CF interest cover (x)	(694.4)	(89.2)	(106.8)	(77.7)	(91.1)

Valuation	2020	2021	2022E	2023E	2024E
<b>Recurring P/E (x) *</b>	<b>65.8</b>	<b>53.3</b>	<b>24.6</b>	<b>23.5</b>	<b>21.6</b>
<b>Recurring P/E @ target price (x) *</b>	<b>81.7</b>	<b>66.3</b>	<b>30.6</b>	<b>29.2</b>	<b>26.9</b>
Reported P/E (x)	65.8	53.3	24.6	23.5	21.6
Dividend yield (%)	0.7	0.8	2.8	3.0	3.2
Price/book (x)	3.2	3.1	2.8	2.7	2.6
Price/tangible book (x)	3.2	3.1	2.8	2.7	2.6
EV/EBITDA (x) **	27.7	20.4	12.0	11.4	10.3
EV/EBITDA @ target price (x) **	35.0	25.9	15.4	14.6	13.3
EV/invested capital (x)	3.7	3.7	3.6	3.5	3.5

\* Pre-exceptional, pre-goodwill and fully diluted \*\* EBITDA includes associate income and recurring non-operating income

Sources: Praram 9 Hospital; FSSIA estimates

## Corporate Governance report of Thai listed companies 2021

EXCELLENT LEVEL – Score range 90-100										
AAV	BCPG	CPALL	GCAP	K	MSC	PLANET	SAMART	SPI	THRE	TVD
ADVANC	BDMS	CPF	GFPT	KBANK	MST	PLAT	SAMTEL	SPRC	THREL	TVI
AF	BEM	CPI	GGC	KCE	MTC	PORT	SAT	SPVI	TIPCO	TVO
AH	BGC	CPN	GLAND	KKP	MVP	PPS	SC	SSSC	TISCO	TWPC
AIRA	BGRIM	CRC	GLOBAL	KSL	NCL	PR9	SCB	SST	TK	U
AKP	BIZ	CSS	GPI	KTB	NEP	PREB	SCC	STA	TKT	UAC
AKR	BKI	DDD	GPSC	KTC	NER	PRG	SCCC	STEC	TMT	UBIS
ALT	BOL	DELTA	GRAMMY	LALIN	NKI	PRM	SCG	STI	TNDT	UV
AMA	BPP	DEMCO	GULF	LANNA	NOBLE	PROUD	SCGP	SUN	TNITY	VGI
AMATA	BRR	DRT	GUNKUL	LH	NSI	DRS	SCM	SUSCO	TOA	VIH
AMATAV	BTS	DTAC	HANA	LHFG	NVD	PSL	SDC	SUTHA	TOP	WACOAL
ANAN	BTW	DUSIT	HARN	LIT	NWR	PTG	SEAFCO	SVI	TPBI	WAVE
AOT	BWG	EA	HMPRO	LPN	NYT	PTT	SEAOIL	SYMC	TQM	WHA
AP	CENTEL	EASTW	ICC	MACO	OISHI	PTTEP	SE-ED	SYNTEC	TRC	WHAUP
ARIP	CFRESH	ECF	ICHI	MAJOR	OR	PTTGC	SELIC	TACC	TRU	WICE
ARROW	CHEWA	ECL	III	MAKRO	ORI	PYLON	SENA	TASCO	TRUE	WINNER
ASP	CHO	EE	ILINK	MALEE	OSP	Q-CON	SHR	TCAP	TSC	ZEN
AUCT	CIMBT	EGCO	ILM	MBK	OTO	QH	SIRI	TEAMG	TSR	
AWC	CK	EPG	INTUCH	MC	PAP	QTC	SIS	TFMAMA	TSTE	
AYUD	CKP	ETC	IP	MCOT	PCSGH	RATCH	SITHAI	TGH	TSTH	
BAFS	CM	FPI	IRPC	METCO	PDG	RS	SMK	THANA	TTA	
BANPU	CNT	FPT	ITEL	MFEC	PDJ	S	SMPC	THANI	TTB	
BAY	COM7	FSMART	IVL	MINT	PG	S & J	SNC	THCOM	TTCL	
BBL	COMAN	GBX	JSP	MONO	PHOL	SAAM	SONIC	THG	TTW	
BCP	COTTO	GC	JWD	MOONG	PLANB	SABINA	SPALI	THIP	TU	
VERY GOOD LEVEL – Score range 80-89										
2S	ASIMAR	CHOW	FLOYD	IT	LOXLEY	OCC	RPC	SKY	TCC	TVT
7UP	ASK	CI	FN	ITD	LRH	OGC	RT	SLP	TCMC	TWP
ABICO	ASN	CIG	FNS	J	LST	PATO	RWI	SMIT	TEAM	UEC
ABM	ATP30	CMC	FORTH	JAS	M	PB	S11	SMT	TFG	UMI
ACE	B	COLOR	FSS	JCK	MATCH	PICO	SA	SNP	TFI	UOBKH
ACG	BA	CPL	FTE	JCKH	MBAX	PIMO	SAK	SO	TIGER	UP
ADB	BAM	CPW	FVC	JMART	MEGA	PJW	SALEE	SORKON	TITLE	UPF
AEONTS	BC	CRD	GEL	JMT	META	PL	SAMCO	SPA	TKN	UPOIC
AGE	BCH	CSC	GENCO	KBS	MFC	PM	SANKO	SPC	TKS	UTP
AHC	BEC	CSP	GJS	KCAR	MGT	PMTA	SAPPE	SPCG	TM	VCOM
AIT	BEYOND	CWT	GYT	KEX	MICRO	PPP	SAWAD	SR	TMC	VL
ALL	BFIT	DCC	HEMP	KGI	MILL	PPPM	SCI	SRICHA	TMD	VPO
ALLA	BJC	DCON	HPT	KIAT	MITSIB	PRIME	SCN	SSC	TMI	VRANDA
ALUCON	BJCHI	DHOUSE	HTC	KISS	MK	PRIN	SCP	SSF	TMILL	WGE
AMANAH	BLA	DOD	HYDRO	KOOL	MODERN	PRINC	SE	STANLY	TNL	WIJK
AMARIN	BR	DOHOME	ICN	KTIS	MTI	PSG	SFLEX	STGT	TNP	WP
APCO	BROOK	DV8	IFS	KUMWEL	NBC	PSTC	SFP	STOWER	TOG	XO
APCS	CBG	EASON	IMH	KUN	NCAP	PT	SFT	STPI	TPA	XPG
APURE	CEN	EFORL	IND	KWC	NCH	QLT	SGF	SUC	TPAC	YUASA
AQUA	CGH	ERW	INET	KWM	NETBAY	RBF	SIAM	SWC	TPCS	
ASAP	CHARAN	ESSO	INSET	L&E	NEX	RCL	SINGER	SYNEX	TPS	
ASEFA	CHAYO	ESTAR	INSURE	LDC	NINE	RICHY	SKE	TAE	TRITN	
ASIA	CHG	ETE	IRC	LEO	NRF	RML	SKN	TAKUNI	TRT	
ASIAN	CHOTI	FE	IRCP	LHK	NTV	ROJNA	SKR	TBSP	TSE	
GOOD LEVEL – Score range 70-79										
A	BGT	CITY	GIFT	JTS	MDX	PK	SGP	SUPER	TQR	YGG
AI	BH	CMAN	GLOCON	JUBILE	MJD	PLE	SICT	SVOA	TTI	ZIGA
AIE	BIG	CMO	GREEN	KASET	MORE	PPM	SIMAT	TC	TYCN	
AJ	BLAND	CMR	GSC	KCM	MUD	PRAKIT	SISB	TCCC	UKEM	
ALPHAX	BM	CPT	GTB	KK	NC	PRAPAT	SK	THMUI	UMS	
AMC	BROCK	CRANE	HTECH	KKC	NDR	PRECHA	SMART	TNH	UNIQ	
APP	BSBM	CSR	HUMAN	KWI	NFC	PTL	SOLAR	TNR	UPA	
AQ	BSM	D	IHL	KYE	NNCL	RJH	SPACK	TOPP	UREKA	
ARIN	BTNC	EKH	IIG	LEE	NOVA	RP	SPG	TPCH	VIBHA	
AS	BYD	EMC	INGRS	LPH	NPK	RPH	SQ	TPIPL	W	
AU	CAZ	EP	INOX	MATI	NUSA	RSP	SSP	TIPIP	WIN	
B52	CCP	F&D	JAK	M-CHAI	PAF	SABUY	STARK	TPLAS	WORK	
BEAUTY	CGD	FMT	JR	MCS	PF	SF	STC	TPOLY	WPH	

**Disclaimer:**

The disclosure of the survey results of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey results may be changed after that date. FSS International Investment Advisory Company Limited does not confirm nor certify the accuracy of such survey results.

\* CGR scoring should be considered with news regarding wrong doing of the company or director or executive of the company such unfair practice on securities trading, fraud, and corruption SEC imposed a civil sanction against insider trading of director and executive

Sources: Thai Institute of Directors Association (IOD); FSSIA's compilation; data as of 26 October 2021

## Anti-corruption Progress Indicator

CERTIFIED										
2S	BCH	CPALL	GC	K	MFC	PE	QLT	SNP	THCOM	TU
7UP	BCP	CPF	GCAP	KASET	MFEC	PG	QTC	SORKON	THIP	TVD
ADVANC	BCPG	CPI	GEL	KBANK	MILL	PHOL	RATCH	SPACK	THRE	TVI
AF	BE8	CPN	GFPT	KBS	MINT	PK	RML	SPALI	THREL	TVO
AI	BEYOND	CSC	GGC	KCAR	MONO	PL	RWI	SPC	TIDLOR	TWPC
AIE	BGC	DCC	GJS	KCE	MOONG	PLANB	S & J	SPI	TIPCO	U
AIRA	BGRIM	DELTA	GPI	KGI	MSC	PLANET	SAAM	SPRC	TISCO	UBE
AKP	BJCHI	DEMCO	GPSC	KKP	MST	PLAT	SABINA	SRICHA	TKS	UBIS
ALPHAX	BKI	DIMET	GSTEEL	KSL	MTC	PM	SAPPE	SSF	TKT	UEC
AMA	BLA	DRT	GUNKUL	KTB	MTI	PPP	SAT	SSP	TMD	UKEM
AMANAHA	BPP	DTAC	HANA	KTC	NBC	PPPM	SC	SSSC	TMILL	UOBKH
AMATA	BROOK	DUSIT	HARN	KWC	NEP	PPS	SCB	SST	TMT	UPF
AMATAV	BRR	EA	HEMP	KWI	NINE	PR9	SCC	STA	TNITY	UV
AP	BSBM	EASTW	HENG	L&E	NKI	PREB	SCCC	STOWER	TNL	VGI
APCS	BTS	ECL	HMPRO	LANNA	NMG	PRG	SCG	SUSCO	TNP	VIH
AQUA	BWG	EGCO	HTC	LH	NNCL	PRINC	SCN	SVI	TNR	WACOAL
ARROW	CEN	EP	ICC	LHFG	NOBLE	PRM	SEAOIL	SYMC	TOG	WHA
AS	CENTEL	EPG	ICHI	LHK	NOK	PROS	SE-ED	SYNTEC	TOP	WHAUP
ASIAN	CFRESH	ERW	IFEC	LPN	NSI	PSH	SELIC	TAE	TOPP	WICE
ASK	CGH	ESTAR	IFS	LRH	NWR	PSL	SENA	TAKUNI	TPA	WIJK
ASP	CHEWA	ETE	ILINK	M	OCC	PSTC	SGP	TASCO	TPP	XO
AWC	CHOTI	FE	INET	MAKRO	OGC	PT	SINGER	TBSP	TRU	ZEN
AYUD	CHOW	FNS	INSURE	MALEE	ORI	PTG	SIRI	TCAP	TRUE	
B	CIG	FPI	INTUCH	MATCH	PAP	PTT	SITHAI	TCMC	TSC	
BAFS	CIMBT	FPT	IRC	MBAX	PATO	PTTEP	SKR	TFG	TSTE	
BAM	CM	FSMART	IRPC	MBK	PB	PTTGC	SMIT	TFI	TSTH	
BANPU	CMC	FSS	ITEL	MC	PCSGH	PYLON	SMK	TFMAMA	TTA	
BAY	COM7	FTE	IVL	MCOT	PDG	Q-CON	SMPC	TGH	TTB	
BBL	COTTO	GBX	JKN	META	PDJ	QH	SNC	THANI	TTCL	
DECLARED										
AJ	CHG	DDD	ETC	JR	MAJOR	NUSA	RS	SSS	TQM	YUASA
ALT	CPL	DHOUSE	FLOYD	JTS	NCAP	NYT	SAK	STECH	TSI	ZIGA
APCO	CPR	DOHOME	GULF	KEX	NCL	OR	SCGP	STGT	VARO	
B52	CPW	ECF	III	KUMWEL	NOVA	PIMO	SCM	TKN	VCOM	
BEC	CRC	EKH	INOX	LDC	NRF	PLE	SIS	TMI	VIBHA	

Level	
Certified	This level indicates practical participation with thoroughly examination in relation to the recommended procedures from the audit committee or the SEC's certified auditor, being a certified member of Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) or already passed examination to ensure independence from external parties.
Declared	This level indicates determination to participate in the Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC)

### Disclaimer:

The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by Thaipat Institute, is made in order to comply with the policy and sustainable development plan for the listed companies of the Office of the Securities and Exchange Commission. Thaipat Institute made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of Thaipat Institute that is a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, FSS International Investment Advisory Company Limited does not confirm, verify, or certify the accuracy and completeness of the assessment results.

Note: Companies participating in Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors (as of 26 October 2021) are categorised into: 1) companies that have declared their intention to join CAC, and; 2) companies certified by CAC.

Sources: The Securities and Exchange Commission, Thailand; \* FSSIA's compilation

## GENERAL DISCLAIMER

### ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSS makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSS has no intention to solicit investors to buy or sell any security in this report. In addition, FSS does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

Company	Ticker	Price	Rating	Valuation & Risks
Praram 9 Hospital	PR9 TB	THB 16.90	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.
Bumrungrad Hospital	BH TB	THB 233.00	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.
Bangkok Dusit Medical Services	BDMS TB	THB 29.00	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.
Bangkok Chain Hospital	BCH TB	THB 17.30	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.
Chularat Hospital	CHG TB	THB 3.54	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Thonburi Healthcare Group	THG TB	THB 67.00	REDUCE	Upside risks to our DCF-based target price include 1) a new Covid wave from a new variant; and 2) big-lot sales of Jin Wellbeing County units.
Vibhavadi Medical Center	VIBHA TB	THB 2.94	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Ramkhamhaeng Hospital	RAM TB	THB 55.25	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) losses from its subsidiary companies.
Principal Capital	PRINC TB	THB 6.10	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) losses from new hospitals.

Source: FSSIA estimates

### Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finasia Syrus Securities Public Company Limited

FSSIA may incorporate the recommendations and target prices of companies currently covered by FSS Research into equity research reports, denoted by an 'FSS' before the recommendation. FSS Research is part of Finasia Syrus Securities Public Company Limited, which is the parent company of FSSIA.

All share prices are as at market close on 10-Oct-2022 unless otherwise stated.

## RECOMMENDATION STRUCTURE

### Stock ratings

Stock ratings are based on absolute upside or downside, which we define as  $(\text{target price}^* - \text{current price}) / \text{current price}$ .

**BUY (B).** The upside is 10% or more.

**HOLD (H).** The upside or downside is less than 10%.

**REDUCE (R).** The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

\* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

### Industry Recommendations

**Overweight.** The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

**Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

**Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

### Country (Strategy) Recommendations

**Overweight (O).** Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Neutral (N).** Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Underweight (U).** Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.